Alterity Therapeutics Limited Total Liabilities
Alterity Therapeutics Limited total liabilities. Based on the latest financial reports, Alterity Therapeutics Limited (PBN) has total liabilities worth €2.65 Million EUR (≈ $3.10 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PBN cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Alterity Therapeutics Limited (2014–2025)
Total liabilities of Alterity Therapeutics Limited from 2014 to 2025. This chart illustrates how Alterity Therapeutics Limited's total liabilities have evolved over time, based on quarterly financial data. Explore PBN long-term investment intensity to see how much of total assets are deployed in long-term investments.
Alterity Therapeutics Limited Competitors by Total Liabilities
The table below lists competitors of Alterity Therapeutics Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SYNergy ScienTech Corp
TW:6558
|
Taiwan | NT$553.11 Million |
|
Duran-Dogan Basim ve Ambalaj Sanayi AS
IS:DURDO
|
Turkey | TL1.36 Billion |
|
Aditya Birla Money Limited
NSE:BIRLAMONEY
|
India | Rs-3.00 Billion |
|
CAG Group AB (publ)
ST:CAG
|
Sweden | Skr193.03 Million |
|
Complex Micro Interconnection Co. Ltd.
TW:6835
|
Taiwan | NT$1.96 Billion |
|
Gagasan Nadi Cergas Berhad
KLSE:0206
|
Malaysia | RM434.75 Million |
|
DY Corporation
KO:013570
|
Korea | ₩448.43 Billion |
|
Gold Terra Resource Corp
V:YGT
|
Canada | CA$1.26 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Alterity Therapeutics Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Alterity Therapeutics Limited's balance sheet.
Liquidity & Leverage Metrics
Alterity Therapeutics Limited Total Liabilities Ratios Explained
Alterity Therapeutics Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 21.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alterity Therapeutics Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alterity Therapeutics Limited (2014–2025)
The table below shows the annual total liabilities of Alterity Therapeutics Limited from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | €3.62 Million ≈ $4.24 Million |
-33.22% |
| 2024-06-30 | €5.43 Million ≈ $6.34 Million |
+20.44% |
| 2023-06-30 | €4.50 Million ≈ $5.27 Million |
-23.57% |
| 2022-06-30 | €5.89 Million ≈ $6.89 Million |
+89.20% |
| 2021-06-30 | €3.12 Million ≈ $3.64 Million |
+13.00% |
| 2020-06-30 | €2.76 Million ≈ $3.22 Million |
-17.83% |
| 2019-06-30 | €3.36 Million ≈ $3.92 Million |
+26.86% |
| 2018-06-30 | €2.64 Million ≈ $3.09 Million |
+66.25% |
| 2017-06-30 | €1.59 Million ≈ $1.86 Million |
-32.53% |
| 2016-06-30 | €2.36 Million ≈ $2.76 Million |
-13.35% |
| 2015-06-30 | €2.72 Million ≈ $3.18 Million |
-31.19% |
| 2014-06-30 | €3.95 Million ≈ $4.62 Million |
-- |
About Alterity Therapeutics Limited
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more